• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 16.88
  • VXN 20.43
  • VXO 17.83
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

AMAG (AMAG Pharmaceuticals Inc)
Last Trade 10.78 Date 8/21/2019
Change % -3.84 % Price Change -0.43
Open 11.21 52 Week High 25.2
High 11.21 52 Week Low 6.81
Low 10.75 Type stock
Volume 985512 Avg Volume 1219002
Prev Close 11.21 Stock Exchange NASDAQ
Company Profile

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat iron deficiency anemia (IDA) in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic for the treatment of IDA in adult patients with chronic kidney disease; and GastroMARK used for delineating the bowel in magnetic resonance imaging (MRI). The company is also developing Feraheme, which is in Phase II clinical trials for use as a vascular-enhanced MRI agent for the assessment of peripheral arterial disease. AMAG Pharmaceuticals has collaborative agreements with 3SBio Inc. for the development and commercialization of Feraheme as an IV iron replacement therapeutic agent in China; Guerbet S.A; Takeda Pharmaceutical Co. Ltd.; and Covidien for marketing GastroMARK in the United States, Canada, and Mexico. The company was founded in 1981 and is based in Lexington, Massachusetts.